The U.S. FDA’s approval of digital therapeutic apps to treat depression marks an innovative step forward in mental health care. The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed tasks on a smartphone app to rewire neural signals. Joining the list of apps, such as